Hormonal
Tirzepatide induces significant weight loss (up to 20.4% with 15mg dose) in individuals with overweight or obesity, comparable to effects observed with bariatric surgery.
For individuals with obesity, tirzepatide offers a non-surgical path to significant weight loss. In clinical trials, the highest dose resulted in an average loss of over 20% of body weight, which is comparable to the results typically seen with bariatric surgery. This makes it a powerful alternative for those who cannot undergo or prefer to avoid surgery.
The use of tirzepatide once weekly provided substantial and sustained reductions in body weight in a dose-dependent manner from -15% with 5 mg reaching up to -20.4% weight change with 15 mg dose versus -3.1% in the placebo group [48]. These observations, especially with the high dose regimen, are comparable to effects observed with bariatric/metabolic surgery [48].
Why this rating
Based on SURMOUNT-1, a large Phase 3 RCT.
Source
The catcher in the gut: Tirzepatide, a dual incretin analog for the treatment of type 2 diabetes mellitus and obesity
Ioannis Lempesis et al. · Metabolism Open · 2022
DOI 10.1016/j.metop.2022.100220
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →